Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia
Corporate Release Lundbeck updates on clinical phase III study for Lu AF35700 in Treatment-Resistant Schizophrenia · Lu AF35700 did not show statistical superiority versus conventional therapy on the primary endpoint (change in Total PANSS) in patients with treatment-resistant schizophrenia (TRS) · Lu AF35700 showed good anti-psychotic effects, was well-tolerated and safe at 10 mg and 20 mg dosages in the study · Further analysis of the data is ongoing Valby, Denmark, 25 October 2018 - H. Lundbeck A/S (Lundbeck)